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Oxidative states exert a signiﬁcant inﬂuence on a wide range of biological and molecular processes and functions. When their
balance is shifted towards enhanced amounts of free radicals, pathological phenomena can occur, as the generation of reactive
oxygen species (ROS) in tissue microenvironment or in the systemic circulation can be detrimental. Epidemic chronic diseases
of western societies, such as cardiovascular disease, obesity, and diabetes correlate with the imbalance of redox homeostasis.
Current advances in our understanding of epigenetics have revealed a parallel scenario showing the inﬂuence of oxidative stress
as a major regulator of epigenetic gene regulation via modiﬁcation of DNA methylation, histones, and microRNAs. This has
provided both the biological link and a potential molecular explanation between oxidative stress and cardiovascular/metabolic
phenomena. Accordingly, in this review, we will provide current insights on the physiological and pathological impact of
changes in oxidative states on cardiovascular disorders, by speciﬁcally focusing on the inﬂuence of epigenetic regulation. A
special emphasis will highlight the eﬀect on epigenetic regulation of human’s current life habits, external and environmental
factors, including food intake, tobacco, air pollution, and antioxidant-based approaches. Additionally, the strategy to quantify
oxidative states in humans in order to determine which biological marker could best match a subject’s proﬁle will be discussed.
1. Introduction
The physiological cellular redox state can be deﬁned as a ﬁne
and suitable balance achieved by the correct proportion of
reactive oxygen species (ROS) within the cell microenviron-
ment. The overall redox events are functional for living cells
and equally involved in the cellular physiological mainte-
nance and in response to a wide range of internal and exter-
nal cues. Reactive oxygen species are intrinsic biological
eﬀectors of important mechanisms such as cell proliferation
and diﬀerentiation, cell cycle progression, host defence,
apoptosis, and migration [1–3]. This suggests their indis-
pensable role in living cells.
Over the years, basic investigations on the pathophys-
iological role of cellular oxidative states on disease have
been clinically conﬁrmed. Speciﬁcally, a causal connection
between enhanced ROS and increased risk of cardiovascular
disease (CVD) has been largely demonstrated [4]. Endothe-
lial dysfunction represents the hallmark of such event. Giving
the endothelium’s multiple roles in vascular homeostasis
including tone, angiogenesis, remodelling, maintenance of
blood ﬂuidity, and as the ﬁrst line of defence against systemic
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insults, the endothelium is more susceptible to ROS-based
variations than other biological systems [5, 6]. In addition,
increased oxidative states normally can coexist with con-
current enhanced levels of local or systemic inﬂammation.
These two events are strongly linked, as they originate a
reinforcing feedback loop, ensuing a potentiated eﬀect.
Interestingly, the pathophysiology of cardiac diseases based
on imbalanced oxidative states can also occur as a conse-
quence of hyperglycaemia, aging, atherosclerosis, or meta-
bolic syndromes, known to negatively exacerbate vascular
dysfunction [7]. Deﬁned mechanisms underlying this eﬀect
have been currently reconsidered and explained by
changes in functional behaviour of the genome induced
by epigenetic mechanisms. The term “epigenetics” refers
to modiﬁcations in the genome without any change in
the primary DNA sequence information, thus only deter-
mining a diﬀerent gene expression regulation of speciﬁc
DNA regions. Accordingly, the aﬀected regions can be
either silenced or activated. Interestingly, epigenetic alter-
ations can be inherited after cellular division, consequently
representing one of the most signiﬁcant known mechanisms
by which living cells may respond to external stimuli and
pass such adaptation to the following generation [8]. Either
acute or chronic stress is able to modify the cellular epige-
netic landscape, producing a wide and diﬀerent range of
eﬀects according to each cell type. In the cardiovascular sys-
tem, combinations of speciﬁc stress responses (hyperglycae-
mia, aging, and obesity) known to be directly related to
CVD can inﬂuence progression of disease as they generate
the “epigenetic memory” in cell populations [7, 9].
Importantly, an unbalanced redox state, caused either by
increase of ROS and/or a reduced scavenging potential in
cells (e.g., reduced antioxidants, scavenging enzyme lowered
activity), deregulates several and diverse intracellular path-
ways related to “redox signalling.” In the heart, changes in
the redox state of cardiac cells, including cardiac smooth
muscle, vascular, and mesenchymal cells, represent a para-
mount source of stress, shown to trigger signalling cascades
ultimately leading to changes in cell epigenetic states. Oxida-
tive stress is able to unlock speciﬁc class IIa histone deacety-
lases (HDACs), whose role consist in repressing pathological
gene expression [10]. Although epigenetic changes possess
both reversible and irreversible features, nevertheless, they
aﬀect cardiac proliferation or generate speciﬁc cell type dys-
function and changes in cellular biology [7].
This has undoubtedly indicated that ROS production and
epigenetic regulation represent an interconnected synergism,
amplifying speciﬁc external factors towards the progression
of pathological cardiac phenotypes. Moreover, life habits
severely impact the link between ROS and epigenetic-
mediated gene expression regulation, conﬁrming that the
control of cellular oxidative stress can be attained by simple
lifestyle modiﬁcations [11, 12]. Accordingly, a beneﬁcial
potential of antioxidant-based therapies for CVD has been
recently encouraged [13]. Yet, enhancing antioxidant system
may in turn be detrimental [14] upsetting redox homeostasis.
Nevertheless, besides the chemical synthetic molecules
already available on the market targeting the binomial ROS
epigenetic, great interest is shown on nonpharmacological
natural antioxidants found in fruits and vegetables, signiﬁ-
cantly enriched in active molecules able to restore physiolog-
ical redox states or simply acting as scavengers. Intriguingly,
the food and recognized lifestyle habits typical of the Medi-
terranean area may be able to directly interfere with our
genome through ROS production [15]. Researchers are
aware that the precise mechanisms by which antioxidants
act still remain to be fully determined, as well as the predic-
tion of possible long-term clinical eﬀects and limitations of
this strategy. Additionally, it is unlikely that the sole restora-
tion of physiological levels of ROSmight ensure the reversion
of cardiac symptoms. It seems more plausible that the man-
agement of the ROS/epigenetic axis could be useful to prime
a preventive protection or to support current cardiac phar-
macological therapies. More importantly, the lack of meth-
odologies to properly quantify the oxidative state of a
human subject represents a current challenge. Therefore,
novel biological tests or markers to deﬁne a personal “ROS-
based proﬁle” are urgently required, in order to evaluate the
eﬃcacy of antioxidant-based strategies.
In this review, we aim to focus on the contribution of
oxidative stress on cardiac pathophysiology with speciﬁc
regard to the pathways by which ROS can eﬀect epigenetic
signals and thus cause the onset of pathological cardiovas-
cular episodes. Additionally, the modality by which exoge-
nous and environmental factors including aging, obesity,
deﬁcient dietary supplements, and smoking could impact
the ROS-dependent epigenetics will be considered. Finally,
novel frontiers to promote healthy lifespan, by employing
a combination of antioxidant approaches and pharmaco-
logical interventions targeting epigenetic mechanisms, will
be discussed.
2. The Oxidative Circuit in the Cardiovascular
System: The Physiological Role Prior To
Oxidative Stress
During embryogenesis, the heart is the ﬁrst organ to be
formed in order to sustain the development of the embryo.
In the early phase of cardiogenesis, cardiomyocytes are in
an active proliferative state, thus requiring an enhanced met-
abolic support to increase their biomass and to allow cell
division. Mitochondria represent the power supply of all
cells, by generating adenosine triphosphate (ATP), the cell
energy currency, through the oxidative phosphorylation
chain reaction. Interestingly, as cardiogenesis requires a met-
abolic overload, the mitochondrial structure transition from
a round-fragmented shape, with an open permeability transi-
tion pore (mPTP), to an elongated structure with an enclosed
mPTP normally occurs [16]. This physiological alteration is
essential to improve the ATP production, suggesting that
the redox state is fundamental for cardiomyocytes matura-
tion in the early phase of cardiogenesis. A further critical
eﬀector during the development of the cardiovascular system
is oxygen concentration. Indeed, the normal value of foetal
arterial blood oxygen pressure is approximately 10mmHg,
meaning that low oxygen concentrations are suﬃcient to
develop the cardiovascular circuit [17]. Speciﬁcally, low
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oxygen concentrations positively modulate hypoxia induc-
ible factor 1α (HIF-1α) subunit activity. Once activated,
HIF-1α transcriptionally ﬁne tunes a panel of angiogenic,
vasculogenic, and foetal heart remodelling genes, including
the most relevant, vascular endothelial growth factor
(VEGF). HIF-1α itself is under redox control with its activity
regulated by S-glutathionyaltion, oxidative posttranslational
modiﬁcation [18]. Moreover, it regulates transcription of an
anaerobic glycolysis-related set of genes, such as the glucose
transporters, the lactate dehydrogenase, and pyruvate dehy-
drogenase kinase. This aspect is crucial, as the largest amount
of the foetal cardiac ATP produced is derived from glycolysis
and oxidation of carbohydrates. Interestingly, during child-
hood, this process is temporarily replaced by the catabolism
of free fatty acids via β-oxidation.
Combined with the oxidative phosphorylation-based
metabolic role, mitochondria in the cardiac tissue are the
principal source of ROS [19]. Reactive oxygen species
include reactive molecules and free radicals derived from
molecular oxygen, such as superoxide anion (·O2−), hydro-
gen peroxide (H2O2), hydroxyl radical (·OH), and the
reactive nitrogen species (RNS) nitric oxide (NO), and perox-
ynitrite (ONOO−). Over the years, ROS have been consid-
ered as damage-causing agents. To date, it has been
demonstrated that subtoxic levels of O2
− and H2O2 can selec-
tively interact with target molecules involved in cell signalling
and regulation. Reactive oxygen species derived from cardiac
mitochondria and NADPH oxidase (Nox) can increase HIF-
1α expression and activity. Nox proteins are a family of seven
membrane-associated multiunit enzymes that catalyse the
reduction of molecular oxygen using NADPH as an electron
donor. Only Nox1, 2, 4, and 5 are present in cardiovascular
tissues [20], and Nox2 has been recently identiﬁed as one of
the key mediators in mechano-chemotransduction during
cardiac contraction [21, 22], whereas endothelial Nox2 is
related to cardiac diastolic dysfunction [5, 6].
To date, strong evidence has supported the beneﬁcial
role of ROS in the adult cardiovascular system. For exam-
ple, NO produced by the endothelial constitutive nitric
oxide synthase (eNOS) is a key regulator of vascular tone
[23]. Nitric oxide increases the cyclic guanosine monopho-
sphate (cGMP) production and activates protein kinase G
(PKG) and smooth muscle cell relaxation [24]. Likewise,
hydrogen peroxide derived from endothelial Nox4 reduces
blood pressure enhancing vasodilation [25]. Hydrogen per-
oxide mediates vasodilation, via modulating the cGMP
pathway or directly acting on PKG [24]. Interestingly,
cardiac-Nox4 protects against left ventricular hypertrophy
through promoting angiogenesis [26]. In contrast, super-
oxide induced from Nox2 in cardiomyocytes contribute
to remodelling postmyocardial infarction [27]. The role
of ROS in vascular smooth muscle cell growth has been
thoroughly investigated. Reactive oxygen species (in partic-
ular O2
− and H2O2) are produced in response to angioten-
sin II, platelet-derived growth factor (PDGF), epidermal
growth factor (EGF), and ﬁbroblast growth factor (FGF)
ligand-receptor interactions. Once generated, ROS trigger
the gene expression of cell proliferation-related genes, such
as c-myc and c-fos.
Interestingly, ROS are able to exert a “contractile regula-
tion” on cardiac muscle. Generally, cardiomyocyte contrac-
tile activity is based on the excitation-contraction coupling
(ECC) process that transduces electrical excitation into con-
traction. During ECC, the membrane potential depolariza-
tion is followed by an inward current of Ca2+ caused by the
opening of the voltage-gated calcium channels (LTCC), lead-
ing to a Ca2+-induced Ca2+ release by the ryanodine receptor
(RyR) on the sarcoplasmic reticulum (SR). The ryanodine
receptor family is composed of three isoforms, all exhibiting
up to 89 cysteine residues per monomer [28]. The RyR2 is the
main characterized redox-sensitive ion channels in the heart.
Oxidizing conditions, and in particular NO, can increase the
channel opening probability through the oxidation of SH
groups, resulting in an increased Ca2+ loss from the SR
[29]. Once released by RyR2, calcium activates myoﬁlaments
during systole by binding troponin C. If LTCC is inactivated
and a K+ current is activated, repolarization occurs through
the synergic regulation of various protein kinases and phos-
phatases. The SR Ca-ATPase SERCA2a is one of the princi-
pal eﬀector of Ca2+ reuptake into the SR, which leads to
relaxation by reducing cytosolic Ca2+. SERCA2a can undergo
redox modiﬁcation on its 25 cysteine residues, especially in
the ATPase subunit [30]. In 2004, Cohen et al. demonstrated
that low concentrations of NO-derived peroxynitrite
(ONOO−) are able to directly increase SERCA2a activity via
S-glutathionylation, promoting relaxation of cardiac muscle
[31]. Likewise, a redox-activation of SERCA2b, the dominant
isoform in vascular smooth muscle cells, with a consequent
reduced intracellular Ca2+ level and vascular relaxation,
has been reported [31]. ROS modulate cellular signalling
through posttranslational modiﬁcation on redox-sensitive
cysteine thiols. Part of the cellular antioxidant pool include
enzymes such as thioredoxin and glutaredoxin which
catalyse the removal of oxidative posttranslational modiﬁ-
cations. The preservation of redox homeostasis is essential,
since increased glutaredoxin-1 can paradoxically attenuate
postischemia neovascularisation [14]. Eﬀective therapy will
be needed to maintain the redox balance between ROS
and antioxidants.
2.1. Oxidative Stress and Cardiovascular Disease Risk Factors.
A large variety of risk factors signiﬁcantly contributes to the
onset of diﬀerent types of cardiac conditions. Interestingly,
most primary risk factors inducing an oxidative stress-
dependent burden are related to life habits and environmen-
tal causes. However, they can be monitored and modiﬁed,
theoretically allowing the potential restoring of the physio-
logical cardiovascular clinical parameters. Among several
cardiovascular dysfunction risk factors, aging represents a
current debated exception, if considered as part of the normal
process of life. Nevertheless, cardiovascular disorders are
extremely frequent among elderly people and additional
genetic, metabolic, pharmacological, or environmental var-
iables may accelerate aging and consequently oxidative
stress, leading to premature propensity to develop cardio-
vascular events.
In the light of this, in the second part of this review,
we will discuss the genesis of oxidative stress induced in
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the setting of major CVD risk factors, including aging,
smoking, and environmental pollution. Moreover, we will
speciﬁcally focus on epigenetic determinants activated by
oxidative stress and leading to cardiovascular disorder,
either when occurring as primary pathological event or
as secondary consequence of main contributor causes.
2.2. Aging. Aging is deﬁned as a multifactorial process
resulting in damage of molecules, cells, and tissues, leading
to a reduced eﬃcacy of functions with diﬀerent pathophysio-
logical consequences and a variety of clinical phenotypes
[32, 33]. Cardiac ﬁbrosis, ventricular hypertrophy, and
myocyte enlargement with decreased cardiac mass represent
the hallmark of aging in the heart [34], and likely induced by
oxidative damage, among others. Accordingly, it has been
demonstrated that an increased release of glutathione,
together with a decreased release of oxidized glutathione,
occurs in aged rat hearts. These alterations suggest that the
metabolic and functional tolerance toward oxidative stress
decreases with age, signiﬁcantly enhancing the predisposition
to CVD [35]. Exposure to highly reactive hydroxyl radicals
may induce several alterations, including peroxidation of
membrane lipids, inactivation of enzymes, and damage of
nucleic acid base weights, which may all aﬀect cell function.
Furthermore, chronic exposure to oxidants, which exceed
endogenous inactivation mechanisms, may result in a pro-
gressive accumulation of these biochemical alterations [36].
Additionally, the endogenous antioxidant system control,
represented by the superoxide dismutase (SOD) and heat
shock protein system (HSP), becomes weaker with aging,
implying a lower resistance to ROS accumulation [37] and
the progressive decline of protection from proteotoxicity
in the mitochondria, apoptosis, and protein aggregation
[38, 39]. Increasing age imbalances mitochondria biogenesis
and mitophagy (i.e., autophagy of mytochondria), which
are both essential for the maintenance of stress resistance
and longevity [40].
An alternative mechanism involved in the aging pro-
cess is represented by sirtuins, members of HDAC class
III family, that, through mono-ADP-ribosyltransferase or
deacetylase activity, are implicated in many biological pro-
cesses, such as DNA repair, cell cycle regulation, apoptosis,
and gene expression [41]. Nuclear SIRT1 mediates antiox-
idant stress responses by activating the FOXO subfamily of
the forkhead family of transcription factors [42]. FOXO sub-
family is involved in a wide range of crucial cellular processes
regulating stress resistance, metabolism, cell cycle arrest, apo-
ptosis, and protein homeostasis, aﬀecting autophagy and
proteasome-related gene expression [43]. SIRT1 has been
related also to mitochondrial biogenesis, acting on the per-
oxisome proliferator activated receptor γ coactivator 1α
(PGC-1α) [44] and HIF-1α [45]. Other sirtuins have been
detected in mammalian mitochondria, such as SIRT3 and
SIRT5 [46]. SIRT3 regulates several enzymes, such as SOD2
and mitochondrial isocitrate dehydrogenase (IDH2), that
are critical in maintaining cellular ROS levels [47]. SIRT5 is
able to bind and activate the carbamoyl phosphate synthetase
(CPS1), which is required for removing ammonia generated
by amino acid catabolism [48] and regulates also ammonia-
induced autophagy [49]. These protective eﬀects are crucial
because ammonia can increase the production of ROS,
inducing the mitochondrial permeability transition (MPT),
known as a common pathway leading to oxidative stress-
induced apoptosis also in cardiomyocytes [48, 50]. Overall,
these evidences indicate that sirtuins are important thera-
peutic targets potentially able to delay the progression of
aging-related pathologies, such as type 2 diabetes or Alzhei-
mer’s disease, and perhaps to extend lifespan. Notably,
sirtuin expression and activity levels decline with age in sev-
eral tissues, implying that induction of long-term enhance-
ment of sirtuin activity represents an interesting challenge
for the scientiﬁc society [51].
2.3. Hyperglycaemia and Obesity. The physiological events
discussed can shift to pathological states in the presence of
clinical insults, such as metabolic disease, obesity, and diabe-
tes [52–55], as well as exogenous and environmental factors
(pollution and tobacco). Lifestyle habits are able to aﬀect
aging, through exacerbating ineﬀective protection from oxi-
dative stress both in adult and in young subjects. Obesity
exerts a great impact on ROS regulation, as it is deﬁned as
chronic low-grade systemic inﬂammation associated with
structural and functional changes in the perivascular adipose
tissue (PVAT), appropriately considered as an endocrine
tissue. This inﬂammatory state leads inevitably to vascular
endothelial and smooth muscle cell dysfunction, thus
increasing cardiovascular risk. All these alterations represent
the foundation of enhanced release of ROS, vascular tone,
and proinﬂammatory factors. It has been demonstrated that
high fat depots within the body result in an enhancement of
energy accumulation, dysfunction of mitochondrial oxida-
tion, and oxidative stress [56]. Recently, Costa et al. demon-
strated that PVAT anticontractile eﬀects are mediated by
ROS directly generated from mitochondrial metabolism
[57]. In fact, PVAT-derived tumor necrosis factor alpha
(TNF-α), known as a mediator of adipose tissue inﬂamma-
tion, can induce mitochondrial oxidative stress in the form
of increased production of.O2
− and consequently conversion
in H2O2 and modulation of the RhoA/ROCK-pathway, a
key player in numerous smooth muscle cell functions,
including contractility [58]. This evidence has suggested that
ROS generation could represent a fundamental mechanism
involved in obesity-associated PVAT vascular dysfunction
[59]. Moreover, systemic alterations strictly associated to
ROS have been observed in obese patients. According to this
scenario, high levels of oxidative stress can be detected both
in overweight young individuals and in obese adults, where
an elevated baseline of proinﬂammatory mediators and of
the biomarker F2-isoprostanes is observed, respectively
[60–62]. Interestingly, F2-isoprostanes are directly corre-
lated with HDL-cholesterol levels, adipocytokines, measures
of adiposity, and total body and abdominal subcutaneous fat
[63]. Despite unequivocal evidence demonstrating a link
between obesity and oxidative stress, speciﬁc prognostic
markers for monitoring the evolution of clinical obesity are
still to be identiﬁed, although some of them have been suc-
cessfully employed to predict the progression of metabolic
CVD in overweight and obese people [64].
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One of the most signiﬁcant medical risk factor of obe-
sity is the insulin resistance state, phenotypically exhibited
as type 2 diabetes, where cells develop a low sensitivity to the
hormone, thus causing hyperglycaemia. Obesity-associated
inﬂammation, that initially aﬀects adipose tissue and liver,
plays a key role in this phenomenon as it inhibits several
insulin-associated signalling pathways, such as insulin recep-
tor substrate 1 (IRS-1) [65], and it increases plasma-free fatty
acid (FFA), thus stimulating lipolysis [66]. In this patho-
logical scenario, oxidative stress could be considered as
both an eﬀector and a consequence, considering that mito-
chondrial function signiﬁcantly contributes to insulin
secretion from pancreatic β-cells [67]. Accordingly, mito-
chondrial increased ROS production promotes accumula-
tion of FFA [68], subsequently increasing the serine/
threonine kinase activity (PKC) that inactivates IRSs [69].
An alternative mechanism of oxidative stress induction
has been described, showing that the increased presence
of FFA may enhance ROS concentration by downregulat-
ing antioxidant enzyme activity, such as peroxisomes and
microsomes [70].
Defects in mitochondrial fatty acid oxidation could be
involved in insulin resistance development, as it induces
increased fatty acid metabolites able to block insulin signal-
ling [68]. These derangements underlie the known direct
detrimental eﬀects of diabetes on cardiac structure and
function, which may contribute to the development of
heart failure and ultimately to death in diabetic patients
[71]. The high ratio of circulating FFA typically detected
in the obese and diabetic population contributes to store
fatty acids in the cardiac tissue and to negatively regulate
mitochondria-based cell metabolism, where fatty acid oxi-
dation instead of glucose oxidation occurs, jeopardizing
ATP production and causing higher oxygen consumption
[72, 73]. This signiﬁcant metabolic change leads to altered
energy availability in cardiomyocytes, to the generation of
lipotoxicity because of the accumulation of ceramide and
diacylglycerol (DAG) inside the myocardium, and to a
gradual decrease of cardiac function [74].
Moreover, SIRT1 is equally and physiologically involved
in the regulation of insulin secretion from pancreatic β-cells,
enhancing ATP production and leading to cell membrane
depolarization and Ca2+-dependent insulin exocytosis [75].
Interestingly, SIRT1 also exerts a protective eﬀect from oxi-
dative stress in pancreatic β-cells by suppressing the proin-
ﬂammatory nuclear factor-kappaB (NF-κB) signalling [76]
and the expression of tyrosine phosphatase-1B, which in turn
negatively regulates the insulin receptor (IR) and IRS-1 [77].
During a lifespan, SIRT1 activity decreases, but adipose tissue
cells of obese subjects already exhibit a reduction, conﬁrming
the exacerbating eﬀects of metabolic diseases on physiologi-
cal states [78].
2.4. Exogenous and Environmental Factors. Beyond
pathophysiology-dependent oxidative stress, it is noteworthy
to consider that the organism is constantly exposed to exog-
enous factors known to induce speciﬁc stress responses.
Among the wide range of environmental elements in the
western society, those related to ecology and lifestyle,
including pollution, smoking, and alcohol, have received a
special focus. Free radicals or substances able to trigger free
radical reactions, contained for example in the form of pol-
lutants in the atmosphere, are usually derived from either
car exhaust pipes and fumes or factories’ waste products. It
has been reported that the exposure to this kind of agents
and in particular to pollutants increases the risk for CVD.
Mechanisms underlying such phenomenon include the
enhancement of the oxidative stress, inﬂammatory response,
and susceptibility to coagulation/thrombosis/atherosclerosis
[79]. Besides, in 2010, during the ﬁrst scientiﬁc statement
on “Air Pollution and Cardiovascular Disease”, the American
Heart Association has drawn the attention on a novel air pol-
lutant, named the particulate matter (PM), currently consid-
ered as a major risk factor for cardiovascular morbidity and
mortality [80]. Furthermore, particles of <0.1μm diameter
(the so-called ultraﬁne particles) are able to inﬁltrate the tis-
sue very easily, showing a preferential localization in the
mitochondria. Similar to other pollutants, the ultraﬁne parti-
cles can induce ROS generation and, subsequently, oxidative
stress in epithelial and macrophage cells [81].
Likewise, cigarettes are considered one of the major
lifestyle-related risk factors for health. Accordingly, it has
been demonstrated that smoking induces multiple side
eﬀects such as inﬂammation, oxidative stress, energy metab-
olism abnormalities, gap junction remodelling, hypertrophy,
and impaired angiogenesis, thus leading to myocardial dam-
age [82]. Interestingly, tobacco increases Nox activity
(known to exert a role in cardiac remodelling) and induces
depletion of antioxidant enzymes, causing oxidative damage
and exacerbating cardiac ﬁbrosis, myocyte hypertrophy,
and systolic dysfunction [83]. Furthermore, smokers exhibit
high levels of circulating inﬂammatory cytokines, such as
TNF-α or IFNs, involved in cardiac remodelling, cell death,
and ROS production [84]. Of note, it has been recently dem-
onstrated that electronic cigarettes (E-cigarettes), a modern
and technological surrogate of traditional tobacco cigarettes,
have unfavourable eﬀects on markers of oxidative stress and
FMD after single use [85]. The smoking-related health risk is
consistently aggravated in the presence of obesity. Recently, it
has been conﬁrmed that this binomial is responsible for
inducing cardiomyocyte apoptosis by both increasing oxida-
tive stress and by mechanisms of inactivation of the AMPK
pathway [86].
Alcohol can also aﬀect the cardiovascular system in a
dose-dependent manner, causing a lower ejection fraction
and left ventricular hypertrophy [87, 88]. It has been demon-
strated that, in the presence of an alcoholic cardiomyopathy,
a reduce activity of respiratory enzymes, lactate dehydroge-
nase, and fatty acid oxidases, combined with an increased
alcohol dehydrogenase activity may occur. The oxidation of
the accumulated acetaldehyde promotes ROS generation,
resulting in organelle damage, lipid peroxidation, and
autophagy [89]. In alcoholic patients, ROS are able to directly
aﬀect atrial ﬁbrillation by exacerbating oxidative modiﬁca-
tions in the myoﬁbrillar creatine kinase and thus inducing
an increase in contractile force [90, 91]. Interestingly, physi-
cal exercise exerts a dual inﬂuence on oxidative states. Specif-
ically, a regular and moderate training stimulates the
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endogenous antioxidant system and the associated adaptive
responses, thus preserving the correct muscle redox balance
[92]. Likewise, an exhaustive aerobic and anaerobic physical
exercise can generate ROS overproduction, leading to oxida-
tive stress-related tissue damages and impaired muscle con-
tractility. Of note, the ﬁnal eﬀect on the redox balance
strictly depends on age, sex, and training level, as well as indi-
vidual susceptibility to oxidative stress injury, which is
known to be determined by genetic and lifestyle factors [93].
2.5. Oxidative Stress and Epigenetics in the Cardiovascular
System and Disease Risk Factors: A Worthy Link to Explore.
It is extremely challenging to unequivocally identify oxida-
tive stress-dependent epigenetic determinants speciﬁcally
involved in the onset of primary cardiovascular disorders
and also to discriminate from those derived by risk factors
(a main summary of epigenetic mechanisms highlighted in
this paragraph is displayed in Figures 1(a) and 1(b)).
The epigenetic modiﬁcations in the heart represent a key
step in the remodelling process, where both acetylations and
methylations target downstream mediators. Importantly,
substantial cardiac stress directly acts on class IIa HDACs,
involved in repressingmainpathological genes [10].Oxidative
stress can disable this activity through the phosphorylation-
independent nuclear export mechanism of HDACs [10].
Pathological cardiac hypertrophy is strictly driven by the
overexpression of members of enhancer factor-2 (MEF-2)
family, which are known to be regulated by class IIa HDACs
[94]. Alternative epigenetic acetylation determinants target-
ing HDAC4 and inﬂuencing cardiac hypertrophy have been
described in combination with enhanced nuclear oxidative
stress caused by Nox4 [94]. In addition to this scenario,
several biological methylation modiﬁcations employ the con-
version of S-adenosyl methionine, a known antioxidant mol-
ecule, to S-adenosyl homocysteine, whose increased levels,
found in patients with CVD [95], are able to directly activate
the DNAmethyltransferases [96]. Intriguingly, this phenom-
enon can be reinforced by a parallel oxidative stress-
dependent epigenetic mechanism (mitoepigenetic) in the
mitochondria, main producers of considerable amount of
ROS following an ischemic insult. The mitochondrial DNA
methyltransferases activity is less sustained compared to that
in the nucleus, but equally enhanced by high levels of homo-
cysteine [97]. From a biological and clinical standpoint, the
hypomethylation negatively drives the angiogenic and endo-
thelial gene expression, resulting in vascular complications.
The mitochondria dynamic also plays a key role in heart fail-
ure, as their damage via enhanced ROS runs parallel to free
calcium in the cardiomyocytes and volume overload [98].
Intriguingly, the hemodynamic stress clearly impacts gene
expression reprogramming via oxidative stress. Accordingly,
a direct association between oxidative stress-dependent epi-
genetic pathways and the trimethylation of histones H3K4
and H3K9, resulting in decreased left ventricular ejection, a
hallmark of chronic heart failure, has been demonstrated
[99, 100].
Likewise, patients with vascular disorders, such as
abdominal aortic aneurism (AAA), display increased expres-
sion of HDAC 1, 2, 4, and 7 in aortic tissues with respect to
healthy subjects, with concomitant changes in DNA methyl-
ation of inﬂammatory cytokine promoters [101]. Interest-
ingly, a main role of ROS in exacerbating the systemic
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inﬂammatory landscape in AAA has been hypothesized,
given the ability of ROS to directly activate histone acetyl-
transferases in several cell types [102]. A similar alteration
of the muscle-speciﬁc histone acetylation proﬁle has been
also reported in vascular smooth muscle cells (VSMCs), in
presence of high levels of oxidized LDL able to combine
HDAC2 and 5-mediated hypoacetylated states with the reac-
tivation of embryonic transcription factors (i.e., Krüppel-like
factor-4) permissive to VSMCs uncontrolled proliferation
[7]. A similar eﬀect can be observed in the lung, where arte-
rial smooth muscle cell proliferation and inhibition of apo-
ptosis are both enhanced by epigenetic attenuation of the
mitochondrial superoxide dismutase (SOD2) [103]. A fur-
ther mechanism has been described in hypertension. The
renin-angiotensin system (RAS) is a major controller of sys-
temic blood pressure. A sustained activation of RAS observed
in hypertension is able to increase ROS levels through
NADPH activation and its catalytic subunits [6, 104]. The
associated upstream epigenetic signal has been linked to the
chromodomain-helicase-DNA-binding protein 2 (CHD2),
an enzyme acting on histone deacetylation and chromatin
remodelling [105] and able to overactivate the transcriptional
site of RAS [106].
The impact of oxidative stress on the cardiac genetic
reprogramming via “pathological” alterations of the epige-
netic machinery is even more substantial if we consider car-
diovascular risk factors strictly associated to enhanced ROS
levels (diabetes, obesity, aging, and life habits). Certainly,
one of the most peculiar and oxidative stress-related epige-
netic modiﬁcation can be found in type 2 diabetes, a major
risk factor for cardiovascular disorders. Diabetic patients
aﬀected by CVD display abnormal genomic cytosine-
guanine (CpG) islands associated with multiple oxidative
stress markers. The CpG sites contain regulatory regions of
the genome, suggesting a potentially direct role of oxidative
stress caused by hyperglycaemia, or in presence of CVD, on
methylation of speciﬁc genes and their expression [107].
Interestingly, patients with acute ischemic stroke exhibit
enhanced levels of systemic 5-methylcytosine [96] with addi-
tional alterations in nucleobases induced by peroxides [108].
Importantly, it has been observed that diabetes can generate
long-term clinical complications even when physiological
glucose levels are restored by pharmacological therapies or
thorough modiﬁcations in patients’ dietary habits and exer-
cise frequency. This phenomenon is well known as metabolic
memory [109]. Metabolic memory has been implicated in the
persistence of epigenetically induced aberrant expression of
ﬁbrotic, antioxidant, and inﬂammatory genes in many cell
types, including vascular smooth muscle and endothelial cells
[110]. For example, hyperglycaemia can lead to increased
levels of mitochondrial ROS in aortic endothelial cells,
inducing long-lasting monomethylation of the histone H3
at the lysine 4 (H3K4) and lysine 9 demethylation
(H3K9) sites in the proximal promoter of the NF-κB sub-
unit p65. The methylation of both histones 3 and 4 can
act synergistically, leading to the aberrant activation of
the downstream proinﬂammatory pathway [110, 111].
Noncoding RNAs, and speciﬁcally microRNAs (miRNA),
known as alternative mediators of epigenetic mechanisms,
have been recently linked to the establishment and mainte-
nance of metabolic memory. MicroRNAs can directly aﬀect
cellular epigenetic states, bymodulating the expression of sev-
eral epigenetic factors [112]. Some miRNAs can also directly
interact with gene promoters and therefore stimulate or
repress their activity inaprocess acknowledgedasRNAactiva-
tion (RNAa) [113]. In addition, diﬀerent from the protein
complexes responsible forDNAandchromatinmodiﬁcations,
miRNAs canbe released into the bloodstreamand captured by
diﬀerent cell types. This phenomenon allows to deregulate the
expression of selected miRNAs and to perpetuate the eﬀect
from one cell to another. Notably, hyperglycaemia, oxidative
stress, and inﬂammation can all modify the proﬁle of circulat-
ingmiRNAs andaﬀect the transcriptional programof vascular
smoothmuscle and endothelial cells, contributing to the exac-
erbation of vascular complications [109]. SomemiRNAs seem
to play a key role upon high glucose levels. Diabetic murine
vascular smooth muscle cells show increased expression of
miR-125b able to target the Suv39h1 gene, responsible of
enhanced expression of inﬂammatory mediators [114]. MiR-
125b has also been shown to be directly responsive to H2O2
in treated human keratinocytes (HaCaT) [115], strengthening
the strict relationship between oxidative stress and changes in
microRNA activity.
Growing evidence is currently supporting a signiﬁcant
relationship between aging-associated diseases and epige-
netic changes [116]. Some eﬀects caused by aging are directly
generated by alterations in gene expression or activity of
DNA and chromatin-modifying enzymes. Histone deacety-
lates, such as SIRT-1, have been shown to decrease in protein
level during physiological aging, leading to age-related
increase in the acetylation of lysine 16 of histone H4
(H4K16). A global hypomethylation of an aged genome has
been associated with decreased activity of DNA methylation
enzymes [9]. The epigenetic eﬀects of oxidative stress associ-
ated to aging have been well described in endothelial cells,
where speciﬁc inhibition of SIRT-1 generates a senescent
phenotype in the HUVEC model system, involving p53 gene
acetylation followed by growth arrest [117]. SIRT-1 activity
inhibition during senescence can also be induced by upregu-
lation of miR-217, which targets SIRT-1 3′UTR and induces
its posttranscriptional silencing in diﬀerent endothelial sys-
tems, including HUVECs and human aortic and coronary
artery endothelial cells [118]. More recently, miR-34a has
been described to have a similar role in mediating cardiac,
endothelial, and endothelial progenitor cell senescence
[119]. A direct eﬀect of oxidative stress on microRNA
expression has been shown on endothelial cells, where
H2O2 treatment increases miR-200 family members, trig-
gering downregulation of the zinc ﬁnger homeobox 1
(Zeb1) transcription factor. These molecular alterations
lead to senescence and apoptosis [120].
Interestingly, longevity is also correlated with metabolic
rates. For instance, production of α-ketoglutarate via oxida-
tive deamination of glutamate is able to inﬂuence chromatin
demethylation [121]. In particular, ROS production is
inversely linked with lifespan. Therefore, ideal strategies aim-
ing at reducing the metabolic rate may possess “rejuvenating
features.” Gene proﬁling analysis in mice subjected to caloric
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restriction has demonstrated that low caloric intake can
modify the aging rate and reduce the accumulation of det-
rimental macromolecules related to oxidation processes,
leading to a 20% longer lifespan [122, 123]. This eﬀect has
been considered protective for telomere length, but against
cardiovascular impairment associated to aging and stress
[124, 125]. Epigenetic mechanisms involving sirtuins, and
speciﬁcally SIRT-1, have been related to this phenomenon.
As already mentioned, another important clinical disease
is obesity, a complex condition determined by a simulta-
neous interaction between genetic features and environmen-
tal factors. Recently, it has been undoubtedly highlighted that
epigenetic changes imprint obesity. Accordingly, obese ado-
lescents display DNA methylation alterations in blood cells
[126]. Adipose tissue is currently considered an important
endocrine organ, secreting various hormones, cytokines (adi-
pocytokines), and free fatty acids (FFAs) [127]. Reactive oxy-
gen species production in obese patients is generated by a
chronic inﬂammatory status promoted by FFA oxidation in
the liver and perpetuated by macrophages and monocytes,
which are constantly stimulated by circulating inﬂammatory
cytokines [128]. It has been shown that stearoyl-CoA desa-
turase 1 (SCD1), an enzyme involved in monounsaturated
fatty acids generation, directly aﬀects inﬂammatory media-
tors production in adipocytes through DNA methylation
[129]. In fact, changes in SCD1 expression are inversely cor-
related with global DNAmethylation changes, where modiﬁ-
cations in CpG methylation of interleukin-10 receptor a
(IL10ra), interleukin-4 receptor a (IL4ra), interleukin-6 sig-
nal transducer (IL6st), and transforming growth factor β1
(TGFβ1) genes are changed by SCD1 overexpression [130].
Functional studies have also revealed a direct association
between chromatin-modifying enzymes and obesity. Genetic
knockout of the Jumonji C-domain containing protein
(Jhdm2a), a H3K9 demethylase, is able to increase mice sus-
ceptibility to obesity by abnormal fat deposition and hyper-
lipidaemia, likely due to PPARα expression decrease in
skeletal muscles and brown fat [131].
Obesity-related inﬂammatory, oxidative, adipogenetic
mechanisms and insulin signalling can be also concomitant
to miRNAs deregulated expression. The heme oxygenase-1
(HO-1) has cytoprotective eﬀects on CVD, and its activity
is reduced in obese mice. Increasing HO-1 activity has shown
functional beneﬁts against insulin resistance and compensa-
tory hyperinsulinemia in animals. MiR-155, miR-183, and
miR-872, which are reduced by insulin treatment of adipo-
cytes, regulate HO-1 activity and levels after insulin
administration [132]. The same miRNAs also contribute
to inﬂammatory cytokines production, oxidative damage,
and apoptosis.
Epigenetic variations can be also induced by exogenous
factors, such as cigarette smoking. Several components in
cigarette smoking can directly alter both methylation and
acetylation balances of chromatin, leading to deregulation
of speciﬁc genes involved in inﬂammation [133]. In particu-
lar, speciﬁc eﬀects on a decreased activity of HDAC2 has
been reported, as well as complete inactivation and proteaso-
mal degradation in the lung cells and macrophages in vivo
[134, 135]. A recent study in vitro on ﬁrst branchial arch-
derived cells has showed that the exposure to cigarette smok-
ing extract (CSE) induces global DNA hypomethylation due
to proteasomal degradation of two main DNA methyltrans-
ferases (DNMT-1 and DNMT-3a) and two methyl CpG-
binding proteins, MeCP-2 and MBD-3 [136].
3. Biological Markers of ROS
The quantiﬁcation of circulating ROS through speciﬁc bio-
markers could represent a promising mean not only to detect
pathological cardiovascular processes but also to predict and
monitor patients’ responses to therapeutic treatments. The
identiﬁcation of which type of molecule would best suit this
purpose is still challenging, as ROS are extremely unstable,
and several physiological process may generate diverse oxi-
dative states and/or be diﬀerentially inﬂuenced by them.
Besides, circulating amounts of ROS might not entirely
reﬂect the local scenario at cellular or tissue level. Therefore,
an indirect measure of ROS could also be informative.
Accordingly, a panel of biomarkers of oxidative stress is cur-
rently available, and it includes molecules that can be modi-
ﬁed by interacting with ROS themselves. Intriguingly, as
DNA, lipids, phospholipids, proteins, and carbohydrates are
selective targets of ROS, they can all mirror the level of oxida-
tive states in patients [137]. Alternatively, the estimation of
the antioxidant counterpart might be relevant at least to
understand an unexpected occurrence of an unbalanced
redox state. Folic acid, contained in vegetables, is a suitable
example to describe how natural oxidants might potentially
function as a litmus test of the cardiovascular state in
humans. In fact, folic acid is able to decrease the circulating
levels of homocysteine in the blood, whose amount is strictly
interdependent to enhanced risks of vascular and cardiac dis-
orders [138]. Notably, some molecules, such as isoprostanes
(IsoPs) and malondialdehyde (MDA), both generated by per-
oxidation of lipids, also hold a prognostic cardiovascular
value. The levels of F2-IsoPs, prostaglandin-like compounds,
are elevated in conjunction with speciﬁc cardiovascular risk
factors, including cigarette smoking, diabetes mellitus, and
myocardial ischemia/reperfusion events. Similarly, isopros-
tanes are also generated during human atherosclerotic
lesions formation [139] and therefore involved in vasocon-
striction, platelet aggregation, and proliferation of vascular
smooth muscle cells [61, 140]. To date, antioxidant therapies
based on the employment of vitamin C and/or E integration
have been shown to decrease the levels of IsoPs [141],
although these observations are not conﬁrmed. Diﬀerently,
MDA, generated in vivo by the peroxidation of polyunsatu-
rated fatty acid, can be easily quantiﬁed in plasma by a color-
imetric assay based on its reaction with thiobarbituric acid
(TBA), generating a ﬁnal product deﬁned as TBARS (TBA
reacting substances) [137]. These latter have been found
decreased in diabetic rats by the antioxidants alpha-lipoic
acid and aminoguanidine [142–144]. Consequently, this
assay represents a useful biological test of oxidative stress
associated with CVD.
“Alternative” free radicals such as nitric oxide (NO), one
of the most powerful vasodilator, could be a further interest-
ing oxidative biological marker. Nitric oxide is known to alter
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both structural integrity and catalytic activity of several pro-
teins by tyrosine nitration and cysteine S-nitrosylation and
glutathionylation. In aging rat hearts, nitration partially
inhibits sarcoendoplasmatic reticulum Ca2+ ATPase 2a
(SERCA2a) activity [145]. Despite this, due to its reduced
half-life, whether or not the quantiﬁcation of NO levels could
accurately provide any relevant clinical information is still to
be fully veriﬁed. In a recent work, Di Gioia et al. have
observed that iron supplementation was able to restore the
detrimental eﬀects of the oxidative/nitrosative damage
involved in SERCA2a-related diabetic heart complication
[146]. In line with this scenario, other studies have reported
that the increase in nitrotyrosine content in diabetic mice
may lead to an enhanced susceptibility to myocardial infarc-
tion [147]. On a molecular level, ROS-responsive genes such
as nuclear factor (erythyroid-derived 2)-like2 (Nrf-2) and
peroxisome proliferator-activated receptor gamma coactiva-
tor 1-alpha (PCG-1α) may be used as biomarkers to assess
cardiovascular redox status [148, 149].
The identiﬁcation of oxidative biomarkers is not only rel-
evant for prognostic reasons but also to understand the com-
plex and assorted response to pharmacological treatments in
human subjects. Direct antioxidants, such as vitamins C and
E, beta carotene, and glutathione, are able to control ROS
ﬂow and prevent the accumulation of their electron excited
metabolites [150]. Pharmacotherapies based on angiotensin
receptor blockers (ARB) [151, 152], statins, HMG-CoA
reductase inhibitor [153], or β-adrenergic receptor blockers
[154, 155], have shown compelling eﬀects on markers of oxi-
dative stress. Therefore, ROS-associated biomarkers may be
positive indicators of the outcome of a speciﬁc therapy.
4. Antioxidant Approach by Natural Agents: The
Road to Detect and to Modify Our Own
Oxidative State
The emerging role of redox mechanisms regulating epige-
netic pathways in a synergistic fashion has led to the develop-
ment of new drugs with antioxidant activity, in order to
target speciﬁc methylated sequences of DNA, histone modi-
ﬁcations, and noncoding RNAs, all strictly related to CVD.
Oxidative stress produces DNA methylation changes [156],
and several inhibitors of this phenomenon, such as the syn-
thetic 5-aza-2-deoxycytidine (a demethylation agent [157]),
may act as cardiac protectors in the presence of a cardiac
pathological condition. Recently, a special attention has been
dedicated to those nonpharmacological natural antioxidants
and active ingredients contained in fruits and vegetables,
including polyphenols, cocoa, and folic acid [158–160]. A
wide number of studies are demonstrating how edible plants
intrinsically exert the highest antioxidant eﬀect in humans,
providing the rationale of their daily consumption in a bal-
anced diet plan. Molecular mechanisms and biological
advantages derived from natural agents are still to be clari-
ﬁed; however, these signiﬁcant experimental observations
have led to the “nutrigenomic” perspective, referring to the
ability of food to interfere with the genome, in other words,
a sort of epigenetic of the food.
Notably, the Mediterranean dietary habit stands out as it
is mainly based on natural antioxidant ingredients [161]. Its
combination with an active lifestyle has been successfully
associated with reduced rates of CVD in the corresponding
populations [162]. It is still arduous to comprehend whether
the beneﬁcial outcome of natural antioxidants in plant-
derived food on the cardiovascular circuit is more related to
a systemic rebalance of the oxidative states rather than a
selective eﬀect. However, strong evidence is supporting this
latter hypothesis. For instance, apocynin (4-hydroxy-3-
methoxy-acetophenone), extracted from the root of Picror-
hiza kurroa (Kutki), is a well-recognized antioxidant [33],
described to prevent excessive collagen deposition and car-
diomyocyte apoptosis in rats [163]. Olive oil, enriched with
polyphenols, is clearly recognized to decrease the levels of
oxidized-LDL and to preserve haemostasis, blood pressure,
and physiological levels of insulin by positively interfering
with the cardiovascular gene expression proﬁle [164, 165].
Curcumin, a member of the ginger family, is another
example since it is able to epigenetically modulate the activity
of HATs and HDACs [166]. Speciﬁcally, it increases the
levels of HDAC2 by preventing its degradation under oxida-
tive and nitrosative stress [133, 134]. Curcumin also exerts
several cardioprotective eﬀects: it activates SIRT1 in cardio-
myocytes, inducing the antiapoptotic gene Bcl-2 and down-
regulating proapoptotic genes such as Bax, beclin-1, and
BNIP3 [167]; it suppresses proﬁbrotic activity in cardiac
ﬁbroblasts [168]; and it reduces oxidative stress-induced
mitochondrial damage in heart cells [169]. In a mouse model
of cardiac hypertrophy, curcumin can suppress the acetylase
p300/CBP, consequently decreasing both inﬂammatory and
ﬁbrotic responses [170, 171].
Moreover, Cui et al. have recently demonstrated protec-
tive eﬀects of α-lipoic acid on male mice subjected to high-
fat diet. Α-lipoic acid restores the redox balance of T cells
reducing signiﬁcantly ROS accumulation through Nrf2
nuclear translocation and upregulation of Nrf2 target genes
as Ho-1 and Prdx1 [172].
Intriguingly, two beverages enriched in natural poly-
phenols, that is, red wine and green tea, which have been
consumed through the centuries in the Mediterranean area
and Asian countries, respectively, are also providing evi-
dence of health beneﬁts. Epicatechins (ﬂavonoid family),
the major component of green tea (but also of cocoa
and grapes), have been demonstrated to restore the
expression of antioxidant enzymes through demethylation
of glutathione-S-transferase P1 (GSTP1) promoter and
the inhibition of DNMT [173]. An indirect positive eﬀect
of the consumption of green tea has been also observed
due of its ability to decrease oxidized LDL, a biological
marker of obesity [174]. Epicatechins contained also in
cocoa would attenuate inﬂammation in human monocytes
subjected to hyperglycaemia by rebalancing appropriate
levels of acetylations and methylations of histone 3 [175].
More importantly, epicatechins have been described to
diminish endothelial activation induced by activated plate-
lets [176]. Resveratrol is another interesting natural mole-
cule, also abundantly present in peanuts, grapes, and other
berries [177], that can act as a potent antioxidant at lower
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concentration compared to other agents in a dose-dependent
fashion [178]. Resveratrol increases the expression of antiox-
idant enzymes, such as glutathione peroxidase, glutathione S-
transferase, and glutathione reductase [179], and acts by
scavenging free radicals as well [180]. Notably, resveratrol is
able to regulate gene expression by epigenetic activity.
Accordingly, both natural and synthetic resveratrol deriva-
tives, such as resveratrol-salicylate, can concurrently act as
DNAmethylation blockers and antioxidant partners by inhi-
biting DNMT3 and DNMT3b enzymes and by decreasing the
expression of myeloperoxidase (MPO), respectively [181].
Resveratrol is also involved in the induction of SIRT1, known
to upregulate eNOS expression via deacetylation of FOXO1
[182]. The activation of FOXO1 results in increased expres-
sion of antioxidant genes, such as manganese superoxide dis-
mutase (Mn-SOD) and catalase [183]. Interestingly, the
beneﬁcial eﬀects of the resveratrol would also encompass
the vascular compartment. Resveratrol upregulates the
expression of HO-1 in artery endothelial and myocardial
cells, reducing the infarcted area and preserving cardiac func-
tion in a rat model of acute myocardial infarction [184, 185].
Moreover, in a recent work, Shen et al. have reported that
resveratrol restores the cardiovascular repair capacity via
peroxisome proliferator-activated receptor-γ (PPAR-γ) and
HO-1 signalling pathways and prevents senescence of endo-
thelial progenitor cells (EPCs), known to be severely
aﬀected by oxidative stress [33, 186]. To date, several pre-
clinical and clinical trials are conﬁrming the eﬃcacy of
resveratrol in treating cardiovascular disorders when
administered for a short period [187]. Accordingly, low
doses (8mg/kg) of resveratrol for one year signiﬁcantly
reduce the number of cardiac risk factors [188].
In addition to natural compounds, researchers are
exploiting many alternative molecules, attempting to solve
the dilemma of whether epigenetic alterations in the cardio-
vascular system induced by oxidative stress may be counter-
acted. Accordingly, HDAC inhibitors are a chemically
synthesized broad-spectrum class of molecules successfully
used for treating several pathologies, including heart disor-
ders [189]. HDACis can be categorized into six distinct
groups: short-chain fatty acids, hydroxamates, cyclic tetra-
peptides, benzamides, electrophilic ketones, and miscella-
neous [190, 191]. Successful examples of clinically eﬀective
HDACis are tributyrin, valproic acid (VPA), trichostatin A
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(TSA), and vorinostat (SAHA), whose administration
reduces signiﬁcantly cardiac ﬁbrosis in a murine model of
acute ischemia by left descending coronary artery ligation
[192–194]. TSA improves myocardial remodelling after
ischemia-reperfusion injury by inhibiting HDAC4 in cardio-
myocytes [192]. Notably, Aune et al. have demonstrated that
entinostat (MS-275), an inhibitor of class I HDAC, exerts a
powerful regenerative eﬀect on restoring contractile heart
function, combined with increased antioxidant properties
when compared to several nonselective and selective HDA-
Cis [195]. To date, the employment of HDACis in cardiovas-
cular disorders is suggesting their clinical validation even in
presence of anti-cancer therapies that may act as pro-
oxidant agents [196]. In particular, it has been demonstrated
that phenylbutyrate (PBA) protects cardiac tissue from oxi-
dative stress generated by the anticancer agent Adriamycin
through the modulation of manganese superoxide dismutase
(MnSOD) [197].
Alternative epigenetic therapies include administration
of miRNA inhibitors and mimics. In fact, ncRNA dysregula-
tions are associated with cardiovascular and metabolic dis-
eases [198, 199]. Circulating miRNAs such as miR-126,
miR-17, miR-145, and miR-222 are currently considered
indicators of cardiovascular risk [200], as their levels in body
ﬂuids or plasma reﬂect the evolution of cardiovascular disor-
ders, including myocardial infarction, heart failure, diabetes
mellitus, stroke, and acute pulmonary embolism [201, 202].
Some miRNAs could also possess prognostic value. In a
recent study, Coskunpinar et al. have observed increased
expression levels of miR-221-3p in acute myocardial infarc-
tion [203]. MicroRNAs are also able to regulate the expres-
sion of genes controlling the generation of ROS, known to
contribute to ﬁbrotic accumulation. Therefore, therapeutic
approaches targeting miRNAs involved in regulating redox
balance involved in ﬁbrosis may represent a novel strategy
for drug development [204]. Understanding how coenzyme
Q10 (CoQ10) supplementation can help diabetic patients
reveals low glutaredoxin-1 levels after treatment [205].
5. Conclusions
A healthy and functional oxidative circuit is indispensable to
preserve physiological homeostasis of the cardiovascular sys-
tem, but it could also reﬂect pathological states when altered.
Consequently, this aspect of the redox state combined with
both experimental observations and preclinical results
highlighting that a strict relationship between unbalanced
ROS production and altered epigenetic modiﬁcations in car-
diovascular disorders, could reveal as prognostic value.
A current challenge is represented by the diﬃculty to dis-
tinguish oxidative stress-dependent epigenetic patterns
induced by primary CVD from those induced by risk factors.
Several epigenetic determinants directly caused by ROS are
still to be discovered, as well as the role of the histonic regu-
lation beyond the solely methylation. Accordingly, a discrete
number of recent reports have conﬁrmed the clinical eﬃcacy
of distinct classes of HDAC inhibitors in CVD [10]. Notably,
oxidative stress forms are hereditable, likely implying deﬁned
hereditable epigenetic changes. This scenario could represent
a solid and suﬃcient background to accumulate over time
further alterations in the genome, that in presence of envi-
ronmental factors prepare for CVD. On the other hand, epi-
genetic mechanisms are reversible. Therefore, we expect to
extend this hypothesis also to those alterations strictly related
to oxidative stress. This could support an alternative thera-
peutic vision of the management of patients in presence of
a cardiovascular insult: oxidative states can be monitored
by intervening on the genome and vice versa by means of
synthetic or natural epigenetic modulators, antioxidants
agents, and healthy life habits.
Despite this, additional drawbacks are predictable. Cellu-
lar oxidative balances and epigenetic proﬁles are likely to be
dissimilar between patients. Moreover, life habits and envi-
ronmental factors also play a key role in this phenomenon,
further exacerbating diﬀerences between subjects and
undoubtedly impacting the binomial relationship between
ROS and epigenetics (Figure 2). Researchers are also seeking
for novel biomarkers by which both physiological and path-
ological oxidative states could be ﬁnely deﬁned, but also
exploited as eligible prognostic criteria. Some drugs targeting
epigenetic signalling may help in the future, but only after
clearly identifying potential tissue or systemic epigenetic
consequent alterations.
We envision that in the future a multiple rather than a
single medical approach based on patient’s oxidative proﬁle
should be encouraged.
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